This principle is not limited to small molecule inducers of protein–protein interactions and can be extended across molecular scale to bispecific antibodies, such as the approved medicine blinatumomab (29) which brings CD19-expressing tumor cells into proximity with cytotoxic T cells, leading to tumor cell lysis. The gene discussed is CD19; the disease is neoplasm.